Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 40
- Registration Number
- NCT05359276
- Locations
- 🇫🇷
Investigational site in France, France, France
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 49
- Registration Number
- NCT05326412
- Locations
- 🇩🇪
Investigational Site Number : 2760004, Peine, Germany
🇺🇸Harvard Medical School - Massachusetts General Hospital (MGH) - Medical Practice Evaluation Center (MPEC)- Site Number : 8400007, Boston, Massachusetts, United States
🇺🇸University of Kansas Medical Center- Site Number : 8400004, Kansas City, Missouri, United States
Comparative Efficacy of Cemiplimab to Historical Standard of Care in France
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 305
- Registration Number
- NCT05302297
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 10
- Registration Number
- NCT05283915
- Locations
- 🇺🇸
Clinical Pharmacology of Miami Site Number : 8400002, Miami, Florida, United States
🇺🇸Nucleus Network Site Number : 8400001, Saint Paul, Minnesota, United States
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 22
- Registration Number
- NCT05282030
- Locations
- 🇺🇸
Clinical Pharmacology of Miami Site Number : 8400002, Miami, Florida, United States
🇺🇸Nucleus Network Site Number : 8400001, Saint Paul, Minnesota, United States
🇺🇸Volunteer Research Group-NOCCR Site Number : 8400003, Knoxville, Tennessee, United States
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
- Conditions
- Fabry Disease
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 104
- Registration Number
- NCT05280548
- Locations
- 🇺🇸
University of Alabama -The Kirklin Clinic- Site Number : 8400010, Birmingham, Alabama, United States
🇺🇸University of California Los Angeles Medical Center- Site Number : 8400008, Los Angeles, California, United States
🇺🇸Emory University School of Medicine - Atlanta- Site Number : 8400009, Atlanta, Georgia, United States
Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 87810
- Registration Number
- NCT05279833
- Locations
- 🇫🇷
Sanofi-Aventis, France, Chilly-Mazarin, France
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- Conditions
- Pruritus
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 208
- Registration Number
- NCT05263206
- Locations
- 🇺🇸
FoxHall Dermatology- Site Number : 8400042, Washington, District of Columbia, United States
🇺🇸Optima Research - Boardman- Site Number : 8400039, Boardman, Ohio, United States
🇯🇵Investigational Site Number : 3920004, Habikino, Japan
Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)
- Conditions
- Immune-mediated Thrombocytopenic Purpura
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4
- Registration Number
- NCT05263193
- Locations
- 🇫🇷
Sanofi-Aventis, Chilly-Mazarin, France
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 22
- Registration Number
- NCT05245071
- Locations
- 🇫🇷
Investigational Site Number : 2500001, Creteil, France
🇯🇵Investigational Site Number : 3920003, Sunto Gun, Shizuoka, Japan
🇯🇵Investigational Site Number : 3920005, Hirakata-shi, Osaka, Japan